Carisma Therapeutics (NASDAQ:CARM) announced Tuesday that its ongoing collaboration with Moderna (NASDAQ:MRNA) to develop cell therapies has been broadened to include two targets for the treatment of autoimmune diseases.
In 2022, the duo teamed up to discover, develop, and commercialize in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapeutics.
With its latest 10-K, the company said the first five research targets under the deal have been designated, and all programs have reached the discovery phase.
As for the newest targets, Carisma (CARM) leads their discovery and optimization, the COVID-19 vaccine maker will lead their clinical development and commercialization.
The company is eligible to receive research funding from Moderna (MRNA) in addition to development, regulatory, and commercial milestone payments, plus royalties on net sales.
Moderna (MRNA) holds an exclusive partnership for the newly-discovered targets, while Carisma (CARM) keeps all rights for remaining targets in autoimmune disease.
